Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Mead Johnson Nutrition Company
Type
Division
Industry Pediatric nutrition
Founded 1905
Headquarters Chicago, Illinois
Evansville, Indiana
(Global Operations Center)
Key people
Aditya Sehgal, EVP Infant and Child Nutrition
Number of employees
7,500 (2017)
Parent Reckitt Benckiser
Website http://www.meadjohnson.com

Mead Johnson Nutrition is a leading manufacturer of infant formula both domestically and globally with its flagship product Enfamil. The company dates back to a firm created by Edward Mead Johnson, one of the co-founders of Johnson & Johnson, who created his own business in 1895, which was renamed Mead Johnson & Company in 1905. The company was majority owned by Bristol-Myers Squibb after an acquisition in 1967, but was spun off in 2009 as an independent firm.

In the year end 31 December 2016, Mead Johnson reported net sales of $3,743 million. Fifty percent of those sales were generated in Asia, 17% in Latin America and 33% in North America/Europe. For the same time period, the company reported total assets of $4,088 million.

In February 2017, British consumer goods company Reckitt Benckiser (RB) bid $16.7 billion for the company.

On June 15, 2017 MJN announced that its merger with Reckitt Benckiser (RB) had been completed. As a result, MJN's common stock is no longer traded on the New York Stock Exchange, effective the announcement date.

Edward Mead Johnson had founded Johnson & Johnson in 1886 together with his brothers. In 1895, Johnson developed a side business called The American Ferment Company to create a digestive aid. In 1897, E. Mead Johnson left the family business to go out into business on his own in Jersey City, New Jersey, and in 1905, the company was re-established as Mead Johnson & Company. The firm's first major infant formula was developed in 1910, and Dextri-Maltose, a carbohydrate-based milk modifier was introduced in 1911, making it the first American product for infants to be clinically approved and recommended by doctors. The firm moved to Evansville, Indiana, in 1915, in the wake of World War I, as part of an effort to have easier access to the raw agricultural ingredients that were needed for its products, which required Johnson to build a series of new plants and factories to replace the ones he had left behind in New Jersey.

Edward Mead Johnson died in 1934, and Lambert Mead Johnson succeeded his father as president, and served in the position until 1955, making him the longest-serving president in company history. D. Mead Johnson was the third generation of the family to serve as chief executive of the firm. During his tenure, which lasted from 1955 until the firm's takeover by Bristol-Myers in 1968, the firm's annual sales tripled to $131 million, and grew to nearly 4,400 employees.

Bristol-Myers reached agreement in August 1967 for a deal under which Mead Johnson would be acquired, with shareholders receiving a mix of common and preferred stock in a deal valued at $240 million. Mead Johnson's net sales in 1966 were $131 million with earnings of $7.3 million.

Bristol-Myers announced in February 2009 that it was going to spin off Mead Johnson to focus on its primary pharmaceutics business, with an initial public offering estimated to bring in $562.5 million and would leave Bristol-Myers with 90% ownership of the firm. A plan offered in November 2009 would allow shareholders of Bristol-Myers to exchange one dollar of stock in that company for $1.11 worth of shares in Mead Johnson for the 133.5 million shares in the firm, which would value the company at $7.7 billion based on the stock's then current closing price. The stock swap was intended to provide a tax-free exchange. CEO James M. Cornelius of Bristol-Myers said that "With a successful execution of this split-off, we fully consider ourselves a BioPharma company".

In February 2017 it was announced that Reckitt Benckiser was in advanced negotiations to acquire Mead Johnson. On February 10, 2017, Reckitt Benckiser Group announced it had agreed to buy Mead Johnson Nutrition Co. for $16.6 billion.

RB's intention was to acquire Mead Johnson Nutrition for $90 per share in cash. In order to effect the transaction, RB incorporated a subsidiary in Delaware into which Mead Johnson Nutrition has merged, with Mead Johnson Nutrition being the surviving entity at completion.

Mead Johnson announced on June 12, 2017 that the final regulator approval to complete the acquisition had been received. On June 15, 2017 the merger was completed and Mead Johnson became the Infant Formula and Child Nutrition (IFCN) Division of RB.

Investment goal date:
Dividends reinvested
Mead Johnson Nutrition Company MJN report Q1 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q3 2017
2017-10-24
--
--
Q2 2017
2017-07-27
--
--
Q1 2017
2017-04-27
0.8000
0.6500
Q4 2016
2017-01-26
0.7800
0.9100
Q3 2016
2016-10-27
0.8700
0.8000
Q2 2016
2016-07-28
0.8800
0.8300
Q1 2016
2016-04-28
0.8700
0.3900
Q4 2015
2016-01-28
0.7800
0.6700
Q3 2015
2015-10-22
0.8000
0.7700
Q2 2015
2015-07-23
0.7600
0.8000
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Alecta Pensionsforsakring, Omsesidigt
4071908
BlackRock Fund Advisors
3315548
BlackRock Inc.
11394361
BlackRock Institutional Trust Company, N.A.
5202187
BROWN ADVISORY INC
2961276
Capital Research Global Investors
5888670
DEUTSCHE BANK AG\
2720332
FARALLON CAPITAL MANAGEMENT LLC
3577500
FMR LLC
5375496
GOLDMAN SACHS GROUP INC
5391172
Invesco Ltd.
2911638
Pentwater Capital Management LP
5060000
STATE STREET CORP
7709238
Vanguard Group, Inc
12206341
York Capital Management Global Advisors, LLC
3476513
Major Shareholders
Name Relationship
Total Shares
Holding stocks
% ()